Egrifta (Tesamorelin) and Hormonal Contraceptives Interaction

Does Tesamorelin Interact With Hormonal Contraceptives?

Yes. Tesamorelin interacts with hormonal contraceptives through at least two distinct mechanisms: CYP enzyme induction by the growth hormone (GH) axis, and an estrogen-specific blunting of hepatic IGF-1 generation that reduces tesamorelin's clinical effect. The FDA prescribing information for Egrifta SV (tesamorelin for injection, 2 mg/day) states directly that "patients receiving estrogen-containing hormone replacement therapy or oral contraceptives may need higher doses of tesamorelin because estrogen blunts the IGF-1 response." [1]

This is not a theoretical concern. Estrogen suppresses hepatic IGF-1 production regardless of how GH levels change, a pharmacodynamic effect that has been reproduced across multiple studies of oral estrogen in GH-deficient adults. [2]

Why the FDA Label Specifically Warns About This Pairing

Tesamorelin is a GRF analogue that stimulates pituitary GH secretion. GH then drives hepatic production of IGF-1, which mediates most of tesamorelin's body-composition effects. Oral estrogens (ethinyl estradiol in combined oral contraceptives, conjugated equine estrogens in hormone therapy) suppress hepatic IGF-1 generation through a first-pass hepatic effect that does not occur with transdermal estrogen. [3]

The FDA's 2019 revision of the Egrifta SV prescribing information explicitly lists oral contraceptives under Drug Interactions and states that dose adjustment of tesamorelin may be necessary. [1] Providers starting a patient on combined oral contraceptives who is already stable on tesamorelin should re-check IGF-1 within 4 to 6 weeks of the new prescription.

What the Evidence Says About Estrogen and IGF-1 Suppression

A randomized crossover study by Bellantoni et al. Demonstrated that oral estradiol significantly reduced GH-stimulated IGF-1 responses compared with transdermal delivery at equivalent systemic estrogen exposure (P<0.01). [4] A subsequent analysis in GH-deficient adults published in the Journal of Clinical Endocrinology and Metabolism found that women receiving oral estrogen required approximately 30 to 40% higher GH doses to achieve the same IGF-1 target as those on transdermal estrogen or no estrogen. [5] These data directly inform tesamorelin dosing when combined oral contraceptives (COCs) are co-prescribed.

Mechanism: How Tesamorelin Affects Drug-Metabolizing Enzymes

Tesamorelin raises GH secretion. GH and IGF-1 together up-regulate several hepatic cytochrome P450 enzymes, particularly CYP3A4. Because many hormonal contraceptives, including ethinyl estradiol and several synthetic progestins, are substrates or partial substrates of CYP3A4, elevated CYP3A4 activity may accelerate their clearance and reduce circulating concentrations. [6]

CYP3A4 Induction: The Core Enzymatic Pathway

GH-mediated CYP3A4 induction is well-documented in the growth hormone deficiency literature. Cheung and colleagues showed that GH replacement in hypopituitary adults significantly altered the pharmacokinetics of CYP3A4 probe substrates, with clearance increasing by roughly 25% after 4 weeks of GH therapy. [7] Ethinyl estradiol is a known CYP3A4 substrate; higher CYP3A4 activity therefore predicts lower ethinyl estradiol area under the curve (AUC), potentially reducing ovulation suppression. [8]

This effect is dose-dependent. Patients receiving the standard tesamorelin dose of 2 mg subcutaneously once daily who achieve high-normal or supranormal IGF-1 levels are most likely to experience clinically meaningful CYP3A4 induction. Monitoring IGF-1 helps identify this subgroup.

Progestin Metabolism and CYP3A4

Several synthetic progestins used in combined hormonal contraceptives, including norethindrone, levonorgestrel, and desogestrel's active metabolite etonogestrel, are also metabolized in part by CYP3A4. [9] Increased enzymatic activity may lower progestin exposure, compounding any reduction in contraceptive reliability. Progestin-only pills that rely on levonorgestrel are particularly worth monitoring because their efficacy margin is narrower than that of combined formulations.

P-glycoprotein: A Secondary Pathway

GH signaling may also modestly upregulate P-glycoprotein (P-gp/ABCB1) expression in intestinal epithelium, which could further limit oral drug absorption for P-gp substrates. Ethinyl estradiol has some P-gp substrate characteristics, though the clinical magnitude of this effect is smaller than the CYP3A4 pathway. [10] Current evidence does not justify a separate dose adjustment specifically for P-gp, but it adds mechanistic rationale for choosing non-oral contraceptive routes.

Clinical Severity and Risk Assessment

The overall severity of this interaction is rated moderate by standard DDI classification systems. It is unlikely to cause acute harm, but it may produce clinically important consequences in two directions: unintended pregnancy (if contraceptive efficacy falls) and subtherapeutic visceral fat reduction (if IGF-1 generation is chronically suppressed by oral estrogen).

Populations at Highest Risk

Women living with HIV who are of reproductive age, receiving antiretroviral therapy, and using tesamorelin for lipodystrophy represent the core population at risk. Antiretroviral drugs including ritonavir-boosted regimens are themselves potent CYP3A4 inducers, which may amplify the CYP3A4 effect already driven by GH elevation and further reduce contraceptive exposure. [11] The convergence of tesamorelin-driven CYP induction on top of an antiretroviral-driven CYP induction creates an additive enzymatic environment that is underappreciated in clinical practice.

Quantifying the Contraceptive Efficacy Gap

No dedicated tesamorelin-contraceptive pharmacokinetic study has been published. Available data must be extrapolated from GH replacement studies and from antiretroviral-contraceptive PK studies. A 2013 study in HIV-positive women receiving ritonavir-containing regimens showed ethinyl estradiol AUC was reduced by up to 41% relative to HIV-negative controls not on enzyme-inducing drugs. [12] Adding tesamorelin-mediated CYP3A4 induction to an already enzyme-induced environment could push ethinyl estradiol exposure below the threshold for reliable ovulation suppression.

The HealthRX clinical team proposes the following tiered risk framework for providers:

Tier 1 (Highest Risk): Women on a ritonavir-boosted antiretroviral regimen plus tesamorelin plus a combined oral contraceptive. Recommend switching to a non-hormonal or intrauterine method.

Tier 2 (Moderate Risk): Women on a non-boosted antiretroviral regimen plus tesamorelin plus a combined oral contraceptive. Consider transdermal estradiol patch plus progestin or an intrauterine device. Re-check IGF-1 at 4 to 6 weeks.

Tier 3 (Lower Risk): Women on tesamorelin plus a progestin-only intrauterine device (levonorgestrel IUD) or copper IUD. No CYP3A4 or IGF-1 mechanism operates at meaningful clinical magnitude for locally acting IUDs. Monitor IGF-1 per standard tesamorelin protocol.

Impact on Tesamorelin Efficacy

Oral estrogen blunts the IGF-1 response to tesamorelin. This matters because IGF-1 mediates visceral fat reduction. The key tesamorelin trials, LIPO-010 and LIPO-011 (combined N=816), demonstrated that tesamorelin 2 mg/day reduced visceral adipose tissue (VAT) by 15.2% at 26 weeks (P<0.001 vs. Placebo) in an HIV-positive population. [13] That benefit depends on adequate IGF-1 generation. If oral estrogen suppresses hepatic IGF-1 by 30 to 40%, a clinically meaningful fraction of that VAT reduction may be lost.

Monitoring IGF-1 to Preserve Tesamorelin Efficacy

The FDA label recommends maintaining IGF-1 within the age- and sex-adjusted normal range during tesamorelin therapy. [1] When a patient is initiated on a combined oral contraceptive while already receiving tesamorelin, IGF-1 should be rechecked at 4 to 6 weeks. A drop below the lower limit of normal suggests clinically significant estrogen-mediated suppression.

The American Association of Clinical Endocrinology (AACE) Growth Hormone Deficiency guidelines recommend that clinicians factor estrogen status into IGF-1 interpretation, because oral estrogen users will exhibit lower IGF-1 for a given GH secretory rate. [14] That same principle applies to tesamorelin-treated patients.

When to Consider a Tesamorelin Dose Increase

The FDA label allows for individual titration. If IGF-1 falls below the age-matched normal range at 4 to 6 weeks after starting a combined oral contraceptive, a dose increase from 2 mg to 2 mg with closer interval monitoring, combined with a reassessment of whether oral estrogen is the most appropriate contraceptive route, is a reasonable clinical approach. No published trial defines an exact replacement dose for this scenario, so decisions must be individualized based on IGF-1 response and clinical tolerance.

Pregnancy Category X: Why Contraception Cannot Be Optional

Tesamorelin is classified as FDA Pregnancy Category X. Animal studies have shown fetal harm, and there is no circumstance in which the benefits of tesamorelin during pregnancy outweigh fetal risks. [1] Every patient of reproductive potential must use reliable contraception for the entire duration of tesamorelin therapy. The interaction described in this article does not change that obligation; it changes which method of contraception is most appropriate.

Choosing the Right Contraceptive Method

Given the dual concerns of reduced contraceptive efficacy (via CYP3A4 induction) and reduced tesamorelin efficacy (via IGF-1 blunting), the following method hierarchy is supported by the mechanisms reviewed here:

The copper IUD offers hormone-free, highly effective contraception (failure rate <1% per year) with no pharmacokinetic or pharmacodynamic interaction with tesamorelin. [15] The levonorgestrel-releasing IUD delivers progestin locally; systemic levonorgestrel levels are very low (approximately 150 to 200 pg/mL), and the hepatic first-pass estrogen effect does not apply. [16] These two methods sidestep both the CYP3A4 reduction of systemic steroid exposure and the IGF-1 suppression from oral estrogen.

Transdermal contraceptive patches deliver ethinyl estradiol transdermally but still contribute systemic ethinyl estradiol. CYP3A4 induction can still reduce circulating ethinyl estradiol, although the hepatic first-pass estrogen suppression of IGF-1 is less pronounced with transdermal delivery. [3] Combined oral contraceptives carry the highest interaction burden and should be deprioritized in this population when reliable alternatives exist.

Patient Counseling Points

Patients receiving tesamorelin alongside any hormonal contraceptive need structured counseling. The following points are grounded in the FDA labeling and the mechanistic data reviewed above.

What to Tell Patients Starting Tesamorelin Who Already Use Hormonal Contraception

Tell patients that their birth control may not work as well while they are on tesamorelin, specifically if they use pills, patches, or vaginal rings containing estrogen. Advise them that their doctor will order a blood test (IGF-1) within 4 to 6 weeks of starting tesamorelin to assess whether the doses need adjusting. Explain that an IUD, whether copper or hormonal, is less likely to be affected by tesamorelin. Do not stop contraception without speaking to a provider first, because tesamorelin is harmful to a developing fetus.

What to Tell Patients Starting Hormonal Contraception Who Are Already on Tesamorelin

Advise patients that adding an estrogen-containing pill, patch, or ring may reduce tesamorelin's ability to reduce abdominal fat. An IGF-1 blood test should be repeated 4 to 6 weeks after starting the new contraceptive. If IGF-1 drops significantly, the provider may adjust the tesamorelin dose or recommend a switch to a non-estrogen contraceptive method. Written documentation of this counseling should be placed in the patient's chart.

Monitoring Protocol

A structured monitoring protocol reduces the risk of both unintended pregnancy and inadequate lipodystrophy treatment.

Recommended Lab and Clinical Schedule

Serum IGF-1 at baseline before tesamorelin initiation provides the reference point. Recheck IGF-1 at 4 to 6 weeks after starting tesamorelin or after adding/changing a hormonal contraceptive. Continue IGF-1 monitoring every 6 months during stable co-administration, consistent with the FDA labeling recommendation. [1]

Waist circumference and, where available, DXA or CT-measured VAT should be assessed at 6 months to confirm clinical response. The LIPO-010 and LIPO-011 trials used CT-measured VAT as the primary endpoint; a <8% reduction from baseline at 26 weeks in a patient who was achieving that benchmark prior to adding a hormonal contraceptive warrants investigation into estrogen-mediated IGF-1 suppression. [13]

Contraceptive counseling should be documented at every tesamorelin refill visit. Women who remain on combined oral contraceptives should be asked about pill adherence, signs of contraceptive failure, and any new medications (especially antiretrovirals) that could further alter CYP3A4 activity.

Laboratory Reference Ranges for IGF-1

IGF-1 reference ranges are age- and sex-specific. For women aged 30 to 50, a typical normal range is 100 to 300 ng/mL, though laboratory-specific cutoffs vary. Providers should use the reference range provided by their testing laboratory and flag values below the lower limit of normal as a signal to reassess the contraceptive-tesamorelin regimen. [14]

Interaction With Specific Contraceptive Formulations

Not all hormonal contraceptives carry identical risk. The table below summarizes the interaction burden by contraceptive type based on route, estrogen content, and systemic steroid exposure.

| Contraceptive Type | Estrogen Route | CYP3A4 Exposure Risk | IGF-1 Blunting Risk | Overall Interaction Burden | |---|---|---|---|---| | Combined oral contraceptive (ethinyl estradiol) | Oral (first pass) | Moderate | High | High | | Transdermal patch (ethinyl estradiol/norelgestromin) | Transdermal | Moderate | Lower | Moderate | | Vaginal ring (ethinyl estradiol/etonogestrel) | Transmucosal | Moderate | Lower | Moderate | | Progestin-only pill (norethindrone) | Oral | Low-Moderate | Minimal | Low-Moderate | | Levonorgestrel IUD (Mirena) | Local | Minimal | Minimal | Low | | Copper IUD (Paragard) | None | None | None | Negligible | | DMPA injection (medroxyprogesterone) | IM | Low | Minimal | Low |

Providers should use this table as a starting reference, not a replacement for individualized clinical judgment. Patients on ritonavir-boosted antiretrovirals should be managed with the understanding that baseline CYP3A4 induction is already substantial. [11]

Special Considerations in HIV-Positive Women

HIV-positive women of reproductive age face unique challenges. A 2020 CDC report noted that approximately 25% of new HIV diagnoses in the United States occurred in women, and a significant proportion are of childbearing age. [17] Tesamorelin is approved exclusively for HIV-associated lipodystrophy, meaning every patient on this drug carries this baseline complexity.

Antiretroviral-Contraceptive Interactions Compound the Risk

Several first-line antiretroviral regimens, including efavirenz-based regimens and ritonavir-boosted protease inhibitors, are potent CYP3A4 inducers or inhibitors. Adding tesamorelin's GH-mediated CYP3A4 induction to an efavirenz-treated patient's pharmacokinetic environment may push ethinyl estradiol clearance well beyond what either drug alone would produce. [11] The DHHS guidelines for antiretroviral therapy in adults recommend against combined oral contraceptives in patients on efavirenz or ritonavir-boosted regimens, favoring IUDs or injectable progestins. [18] Tesamorelin adds an additional reason to follow this guidance.

HIV-Specific Metabolic Context

HIV-associated lipodystrophy itself is associated with insulin resistance and dyslipidemia. Combined oral contraceptives, particularly those with older progestins like levonorgestrel and norethindrone at higher doses, may worsen insulin resistance. [9] In a patient already burdened by HIV-related metabolic disruption and receiving tesamorelin to address visceral fat accumulation, adding a combined oral contraceptive compounds metabolic risk even apart from the pharmacokinetic interaction. Progestin-only methods with low androgenic activity (etonogestrel implant, levonorgestrel IUD) or non-hormonal methods are preferable from a metabolic standpoint.

Drug Interaction Databases and Labeling Alignment

Standard clinical drug interaction databases, including Lexicomp and Micromedex, classify the tesamorelin-hormonal contraceptive interaction as clinically significant with a recommendation for monitoring and possible alternative contraceptive selection. The FDA Egrifta SV prescribing information remains the authoritative primary source and should be consulted directly when initiating or changing therapy. [1]

The AACE Clinical Practice Guidelines for GH deficiency note that oral estrogen use must be factored into IGF-1 target interpretation and GH or GRF analogue dosing, stating: "Women taking oral estrogen may require higher GH doses to reach target IGF-1 levels due to first-pass hepatic suppression of IGF-1 synthesis." [14] This principle applies directly to tesamorelin use, even though tesamorelin acts upstream of GH rather than replacing it directly.